Kanishk Kumar – Hemophilia A Pipeline 2025: New Therapies Changing Patient Care
Kanishk Kumar, Digital Marketing Executive at DelveInsight Business Research LLP, posted on LinkedIn:
“Hemophilia A Pipeline 2025: New Therapies Changing Patient Care
The Hemophilia A treatment landscape is evolving fast in 2025. Researchers and companies are pushing forward gene therapies, long-acting factor replacements, and innovative prophylactic options, all aimed at improving patients’ quality of life and reducing the burden of frequent treatments.
Recent Highlights:
On 10 October 2025, Roche initiated a Phase I/II study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of NXT007 in patients with severe or moderate Hemophilia A.
On 08 October 2025, BioMarin Pharmaceutical Inc. announced a Phase III study to assess the safety and effectiveness of valoctocogene roxaparvovec in combination with prophylactic corticosteroids in patients with severe Hemophilia A.
Key companies leading the way include Roche, Chugai Pharmaceutical Co., Ltd. , Shire , Pfizer , BioMarin Pharmaceutical Inc., Sinocelltech Ltd., Bayer, Ultragenyx , Spark Therapeutics, Inc., Octapharma, APCINTEX LIMITED , Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Expression Therapeutics, Inc., CSL and others.”
See the full Hemophilia A Pipeline 2025 report and track the therapies shaping the future here.
Stay updated with Hemostasis Today.
-
Sep 24, 2026, 08:55Andres Gudino: Clot Characterization Through Hounsfield Units in Ischemic Stroke
-
Sep 24, 2026, 06:52Gina Sado: Screening-Detected Atrial Fibrillation Carries High Risk of Heart Failure
-
Sep 24, 2026, 06:33Benjamin Vipler: Optimal Oral Anticoagulation Choice in Atrial Fibrillation and Advanced CKD
-
Sep 24, 2026, 06:08Christopher Salerno: AI-Powered At-Home Anemia Screening Advances Telehealth Access
-
Sep 24, 2026, 05:38Aya Qattan: When a Normal CBC Does Not Mean Normal Iron Status
-
Sep 24, 2026, 05:11Mastering Warm Autoimmune Hemolytic Anemia Diagnosis and Practice – ASH Education
-
Sep 23, 2026, 16:04Monia Ezzalfani: Advancing Patient-Centered Care in Hemophilia A and B
-
Sep 23, 2026, 15:49Bilge Başak: How Activated PRP Modulates Osteoarthritic Chondrocyte Function
-
Sep 23, 2026, 14:50Mbonjo Bitsie Dora: Strengthening Sickle Cell Care Through Education, Awareness and Innovation